ArticleIn vivo (Athens, Greece)
The Geriatric Nutritional Risk Index Predicts Tolerability of Lenvatinib in Patients With Hepatocellular Carcinoma.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.
- Prognostic impact of geriatric nutritional risk index on patients with urological cancers: A meta-analysis.Frontiers in oncology · 2022Pooled it
- Predictive Value of Nutrition Indices in Advanced Hepatocellular Carcinoma Patients Treated With Lenvatinib.The Kaohsiung journal of medical sciences · 2026Article
- Development of a PNI-Based Prognostic Model for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib-Based Triple Therapy.Journal of hepatocellular carcinoma · 2026Article
- Geriatric nutritional risk index as a predictor of prognosis in hepatocellular carcinoma: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.Scientific reports · 2025Article
- Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives.Journal of hematology & oncology · 2024Review
- Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).American journal of cancer research · 2024Review
- A Low Geriatric Nutritional Risk Index Is Associated with Low Muscle Volume and a Poor Prognosis among Cirrhotic Patients.Medicina (Kaunas, Lithuania) · 2023Article
- Correlation between preoperative systemic immune inflammation index, nutritional risk index, and prognosis of radical resection of liver cancer.World journal of gastrointestinal surgery · 2023Article
- Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors.Human vaccines & immunotherapeutics · 2023Article
- Low geriatric nutritional risk index predicts poor prognosis in patients with cirrhosis: a retrospective study.Frontiers in nutrition · 2023Article
- Effect of Nutritional Index on Lenvatinib Treatment Retention Rates in Unresectable Hepatocellular Carcinoma.In vivo (Athens, Greece)Article
- Evaluation of Lung Adverse Events Associated With Lenvatinib: A Post-marketing Surveillance Study.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimWe aimed to investigate the association between The Geriatric Nutritional Risk Index (GNRI) and the tolerability of lenvatinib in patients with hepatocellular carcinoma (HCC). PATIENTS AND
methodsWe retrospectively evaluated 61 HCC patients treated with lenvatinib and compared those with low GNRI (≤98, n=26) to those with high GNRI (>98, n=35).
resultsThe discontinuation of lenvatinib due to adverse events was more frequent in the low GNRI group (46.2%) than in the high GNRI group (17.1%) (p=0.014). Multivariate analysis revealed that low GNRI (p=0.014), hypothyroidism (model 1 p=0.021, model 2 p=0.013), and advanced age (p=0.026) were independently associated with the discontinuation of lenvatinib. The progression-free survival in the low GNRI group was significantly shorter than that in the high GNRI group (p=0.047).
conclusionThe GNRI might be independently associated with the tolerability of lenvatinib in patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.